Benzinga
Benzinga
Benzinga
sábado, septiembre 19

Ensysce Biosciences Inc

ENSCNASDAQ
Trade with Public
Trade with Public
$0.4581
0.00561.24%
al cierre: Sep 18, 5:00 PM EST
$0.4500
-0.0081-1.77%
After hour: 7:53 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararInforme de acciones

Ensysce Biosciences Financials

Ensysce Biosciences (ENSC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Ensysce Biosciences Q2 EPS $(0.20) Beats $(0.50) Estimate, Sales $1.164M Beat $1.000M Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.50) by 60 percent. This is a 74.68 percent increase over losses of $(0.79) per share from
Benzinga Newsdesk

PRO
Ensysce Biosciences Q1 EPS $(0.52) Beats $(0.73) Estimate, Sales $960.999K Miss $1.900M Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.73) by 28.77 percent. This is a 62.59 percent increase over losses of $(1.39) per share
Benzinga Newsdesk

PRO
Ensysce Biosciences Q4 EPS $(0.75) Misses $(0.70) Estimate, Sales $1.882M Beat $500.000K Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.70) by 7.14 percent. This is a 74.14 percent increase over losses of $(2.90) per share
Benzinga Newsdesk

PRO
Ensysce Biosciences Q3 EPS $(1.29) Misses $(0.84) Estimate, Sales $493.104K Miss $700.000K Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(0.84) by 52.66 percent. This is a 229 percent decrease over earnings of $1.00 per share
Benzinga Newsdesk

PRO
Ensysce Biosciences Q2 EPS $(0.79) Beats $(1.18) Estimate, Sales $1.371M Beat $650.000K Estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(1.18) by 33.05 percent. This is a 76.06 percent increase over losses of $(3.30) per share
Benzinga Newsdesk

PRO
Ensysce Biosciences Q1 EPS $(1.39) Beats $(3.02) Estimate, Sales $1.32M Up From $305.72K YoY

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.39) per share which beat the analyst consensus estimate of $(3.02) by 53.97 percent. This is a 83.07 percent increase over losses of $(8.21) per share
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved